NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000056193

Registered date:20/11/2024

Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedRheumatoid arthritis
Date of first enrollment2024/11/22
Target sample size
Countries of recruitmentJapan
Study typeOthers,meta-analysis etc
Intervention(s)

Outcome(s)

Primary OutcomeSeroconversion of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis.
Secondary OutcomeFactors associated with the development of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1)Unable to assess frequency of Anti-CCP antibody seroconversion 2)Reviews, meta-analysis papers and Research plan 3)Conference abstracts

Related Information

Contact

public contact
Name Ryoko Asano
Address 2630 Sugitani, Toyama, Japan. Japan 930-0194
Telephone 076-434-7287
E-mail aryoko@med.u-toyama.ac.jp
Affiliation University of Toyama Faculty of Medicine The First Department of Internal Medicine
scientific contact
Name Masaru Kato
Address 2630 Sugitani, Toyama, Japan. Japan
Telephone 076-434-7287
E-mail ktmasaru@med.u-toyama.ac.jp
Affiliation University of Toyama Faculty of Medicine The First Department of Internal Medicine